Geron GERN Commercial expenses — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Geron in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Geron's commercial expenses — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Geron's commercial expenses — SG&A?
- Geron (GERN) reported commercial expenses — SG&A of $17M in Q1 2026.
- How has Geron's commercial expenses — SG&A changed year-over-year?
- Geron's commercial expenses — SG&A decreased by 15.0% year-over-year, from $20M to $17M.
- What is the long-term trend for Geron's commercial expenses — SG&A?
- Over 2 years (2023 to 2025), Geron's commercial expenses — SG&A has grown at a 71.9% compound annual growth rate (CAGR), from $27.4M to $81M.
- What does commercial expenses — SG&A mean?
- This metric represents the operating costs associated with the commercialization, marketing, and administrative support of a company's pharmaceutical products. It captures the investment required to build sales infrastructure, manage regulatory compliance, and execute market access strategies for drug launches. Monitoring these expenses provides insight into the company's operational efficiency and the scale of its commercial footprint as it transitions from clinical development to product commercialization.